Buscar
Mostrando ítems 41-50 de 122
Safety and Non-Inferiority Evaluation of Two Immunization Schedules with an Inactivated SARS-CoV-2 Vaccine in Adults: A Randomized Clinical Trial
(MDPI, 2022)
Several vaccines have been developed to control the COVID-19 pandemic. CoronaVac (R), an inactivated SARS-CoV-2 vaccine, has demonstrated safety and immunogenicity, preventing severe COVID-19 cases. We investigate the ...
Influence of age on the effectiveness and duration of protection in Vaxzevria and CoronaVac vaccines (Preprint)
(BMJ Publishing Group, 2021)
Effectiveness of CoronaVac in children 3–5 years of age during the SARS-CoV-2 Omicron outbreak in Chile
(2022)
The outbreak of the B.1.1.529 lineage of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Omicron) has caused an unprecedented number of Coronavirus Disease 2019 (COVID-19) cases, including pediatric hospital ...
Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
(Nature Research, 2022)
Safety and Immunogenicity of an Inactivated Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine in a Subgroup of Healthy Adults in Chile
(2021)
Abstract Background The development of effective vaccines against coronavirus disease 2019 is a global priority. CoronaVac is an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine with promising ...
Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: a population-based cohort study
(Elsevier Ltd.United Kingdom, 2022)